Free Newsletter
Analysts buoy Cell Genesys' hope for GVAX
Shares of Cell Genesys got hit hard last week after the company announced that it was being forced to halt a late-stage trial of its cancer vaccine due to a higher death rate among patients taking a combination of GVAX and Taxotere. Researchers reported that 67 people in the GVAX arm had died compared to 47 in the group taking Taxotere alone.
But not all the analysts were ready to write off the company's prospects. The biotech's share price bounced 31 percent the day after it plunged 72 percent, largely because some analysts believe that GVAX can still win an approval. Previous trials have demonstrated efficacy and a second late-stage trial is still underway.
"The most substantial market opportunity for GVAX, we think, remains intact," said Pamela Bassett of Cantor Fitzgerald, in a reference to patients with early stage prostate cancer and those who are treatment naïve.
- read the AP report
Related Articles:
Deaths force halt to Cell Genesys cancer vaccine trial
Cell Genesys scores $320M blockbuster deal
Cell Genesys gains $75M in R&D funds
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
